You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases » Diabetes, Type II
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

home:diseases:diabetes2 [02.19.2019] – [Patients experiences] sallieqhome:diseases:diabetes2 [09.14.2022] (current) – external edit 127.0.0.1
Line 12: Line 12:
 Major long term symptoms and effects of diabetes include retinopathy, neuropathy, nephropathy, congitive dysfunction, foot sores and amputations of limbs.  Major long term symptoms and effects of diabetes include retinopathy, neuropathy, nephropathy, congitive dysfunction, foot sores and amputations of limbs. 
  
-===== Recent Research =====+===== Research =====
  
  
-Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.  (({{pubmed>long:22418908}})) +Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.  (({{pmid>long:22418908}})) 
  
  
-Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.  (({{pubmed>long:25275251}})) +Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.  (({{pmid>long:25275251}})) 
  
-Adenosine is an endogenous metabolite that is released from all tissues and cells including liver, pancreas, muscle and fat, particularly under stress, intense exercise, or during cell damage.  (({{pubmed>long:23460239}})) +Adenosine is an endogenous metabolite that is released from all tissues and cells including liver, pancreas, muscle and fat, particularly under stress, intense exercise, or during cell damage.  (({{pmid>long:23460239}})) 
  
-The effects of diabetes on Adenosine A2BR receptor transcription and signaling    (({{pubmed>long:21270276}})) +The effects of diabetes on Adenosine A2BR receptor transcription and signaling    (({{pmid>long:21270276}})) 
  
-Results indicate a relationship between muscular TLR4, p-AMPK and NF-κB content and insulin sensitivity. The study also highlights that in situations of insulin resistance, such as in diabetic subjects, metformin treatment may prevent attenuation of activation of the inflammatory pathway.  (({{pubmed>long:28791487}})) +Results indicate a relationship between muscular TLR4, p-AMPK and NF-κB content and insulin sensitivity. The study also highlights that in situations of insulin resistance, such as in diabetic subjects, metformin treatment may prevent attenuation of activation of the inflammatory pathway.  (({{pmid>long:28791487}})) 
  
-Here, we investigated the hypothesis that the activation of the low-affinity adenosine receptor, the A2B receptor (A(2B)R), promotes glucose uptake in neurons and astrocytes, thereby linking brain activity with energy metabolism.   (({{pubmed>long:26446689}})) +Here, we investigated the hypothesis that the activation of the low-affinity adenosine receptor, the A2B receptor (A(2B)R), promotes glucose uptake in neurons and astrocytes, thereby linking brain activity with energy metabolism.   (({{pmid>long:26446689}})) 
  
-Our results illustrate that macrophage A2bAR signaling is needed and sufficient for relaying the protective effect of the A2bAR against HFD-induced tissue inflammation and insulin resistance in mice.  (({{pubmed>long:24892847}})) +Our results illustrate that macrophage A2bAR signaling is needed and sufficient for relaying the protective effect of the A2bAR against HFD-induced tissue inflammation and insulin resistance in mice.  (({{pmid>long:24892847}}))  
 + 
 +This trial aims to determine the effects of resistant starch (RS) subtype 2 (RS2) on glycemic status, metabolic endotoxemia and markers of oxidative stress.  (({{pmid>long:    26655398}})) 
 + 
 +Among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency, vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo. (({{pmid>long:31173679}}))
  
  
Line 34: Line 38:
  
  
-Diet and exercise are the traditional lifestyle interventions used to prevent and treat type 2 diabetes. Different components of the diet can affect the course of type 2 diabetes, but a low carbohydrate diet appears to be giving the most significant results. (({{pubmed>long:19099589}})) (({{pubmed>long:19419563}})) (({{pubmed>long:18397522}})) +Diet and exercise are the traditional lifestyle interventions used to prevent and treat type 2 diabetes. Different components of the diet can affect the course of type 2 diabetes, but a low carbohydrate diet appears to be giving the most significant results. (({{pmid>long:19099589}})) (({{pmid>long:19419563}})) (({{pmid>long:18397522}})) 
  
-Both endurance and resistance exercise yield improvements in many aspects of the metabolic derangements in diabetes type II.(({{pubmed>long:17656625}})) +Both endurance and resistance exercise yield improvements in many aspects of the metabolic derangements in diabetes type II.(({{pmid>long:17656625}})) 
  
 Sulfonylureas, biguanids, glitazones, GLP-1 analogs, DPP-4 inhibitors and insulin are the main medication groups used to treat type 2 diabetes. These medications have modulation of insulin funcion, increments in insulin sensitivity and increments in insulin production as their main mechanisms of action.  Sulfonylureas, biguanids, glitazones, GLP-1 analogs, DPP-4 inhibitors and insulin are the main medication groups used to treat type 2 diabetes. These medications have modulation of insulin funcion, increments in insulin sensitivity and increments in insulin production as their main mechanisms of action. 
Line 43: Line 47:
 ===== Evidence of infectious cause ===== ===== Evidence of infectious cause =====
  
-Rubella virus-induced diabetes in the hamster.  (({{pubmed>long:3530856}}))+Rubella virus-induced diabetes in the hamster.  (({{pmid>long:3530856}}))
 <blockquote>The congenital rubella syndrome provides the best documentation in humans that a viral infection is associated with the subsequent development of insulin-dependent diabetes mellitus.</blockquote> <blockquote>The congenital rubella syndrome provides the best documentation in humans that a viral infection is associated with the subsequent development of insulin-dependent diabetes mellitus.</blockquote>
  
Line 51: Line 55:
 The presence of bacterial components in blood predicts the onset of diabetes mellitus in a large general population recounts lead author Jacques Amar from the Centre Hospitalier Universitaire in Toulouse, France. The investigators determined the concentration of 16S rDNA in blood at baseline and assessed its relationship with incident diabetes mellitus and obesity over a follow-up period of 9 years.  The presence of bacterial components in blood predicts the onset of diabetes mellitus in a large general population recounts lead author Jacques Amar from the Centre Hospitalier Universitaire in Toulouse, France. The investigators determined the concentration of 16S rDNA in blood at baseline and assessed its relationship with incident diabetes mellitus and obesity over a follow-up period of 9 years. 
  
-Linda Koch - comment in [[http://www.nature.com/nrendo/journal/v8/n1/full/nrendo.2011.192.html?WT.ec_id=NRENDO-201201|Nature reviews: Endocrinology]]  +Linda Koch - comment in [[https://www.nature.com/nrendo/journal/v8/n1/full/nrendo.2011.192.html?WT.ec_id=NRENDO-201201|Nature reviews: Endocrinology]]  
 </blockquote> </blockquote>
  
Line 71: Line 75:
 CONCLUSIONS/INTERPRETATION: CONCLUSIONS/INTERPRETATION:
  
-16S rDNA was shown to be an independent marker of the risk of diabetes. These findings are evidence for the concept that tissue bacteria are involved in the onset of diabetes in humans.(({{pubmed>long:21976140}}))  +16S rDNA was shown to be an independent marker of the risk of diabetes. These findings are evidence for the concept that tissue bacteria are involved in the onset of diabetes in humans.(({{pmid>long:21976140}}))  
  
 </blockquote> </blockquote>
Line 79: Line 83:
  
 To what extent microbes contribute to the global diabetes burden, and to what extent antimicrobial therapy can prevent or reverse the disease, has to a limited degree been investigated in clinical trials (see below). To what extent microbes contribute to the global diabetes burden, and to what extent antimicrobial therapy can prevent or reverse the disease, has to a limited degree been investigated in clinical trials (see below).
-However, the finding that obese and diabetic patients have higher levels of lipopolysaccharides (LPS, a bacterial product) in their bodies and that insulin level is correlated with the amount of LPS make a strong argument for infectious cause.(({{pubmed>long:17090751}})) +However, the finding that obese and diabetic patients have higher levels of lipopolysaccharides (LPS, a bacterial product) in their bodies and that insulin level is correlated with the amount of LPS make a strong argument for infectious cause.(({{pmid>long:17090751}})) 
  
-Inflammation (which is intimately associated with infection) induced by cytokines (({{pubmed>long:20056828}})) (({{pubmed>long:12453891}})) (({{pubmed>long:16427608}})) leads to insulin resistance. +Inflammation (which is intimately associated with infection) induced by cytokines (({{pmid>long:20056828}})) (({{pmid>long:12453891}})) (({{pmid>long:16427608}})) leads to insulin resistance. 
  
-Abrogation of inflammation ameliorates insulin resistance. (({{pubmed>long:20445103}})) (({{pubmed>long:2038201}})) (({{pubmed>long:20159859}})) (({{pubmed>long:19515743}})) +Abrogation of inflammation ameliorates insulin resistance. (({{pmid>long:20445103}})) (({{pmid>long:2038201}})) (({{pmid>long:20159859}})) (({{pmid>long:19515743}})) 
  
-Deletion of the insulin receptor in myeloid cell lines inhibits development of insulin resistance.(({{pubmed>long:20463885}}))+Deletion of the insulin receptor in myeloid cell lines inhibits development of insulin resistance.(({{pmid>long:20463885}}))
  
-Further, beta amyloid, which has been identified as an antimicrobial peptide,(({{pubmed>long:20209079}})) is found in increased amounts in pancreatic beta cells of type 2 diabetics,(({{pubmed>long:18950899}})) hinting at the presence of microorganisms as a cause of the malfunction and destruction of the beta cells.+Further, beta amyloid, which has been identified as an antimicrobial peptide,(({{pmid>long:20209079}})) is found in increased amounts in pancreatic beta cells of type 2 diabetics,(({{pmid>long:18950899}})) hinting at the presence of microorganisms as a cause of the malfunction and destruction of the beta cells.
  
 <blockquote>"The VDR is responsible for expression of the Insulin receptor substrate (reference needed). Fix the VDR dysfunction and you will stymy the diabetes. In addition, those of our members who have had high blood-glucose levels have not suffered from having those high BG levels to the same extent that a 'normal' individual would have done, as the VDR activation, and the Angiotensin receptor blockade, both produced by the Olmesartan, have protected their bodies from the expected damage." Trevor Marshall </blockquote> <blockquote>"The VDR is responsible for expression of the Insulin receptor substrate (reference needed). Fix the VDR dysfunction and you will stymy the diabetes. In addition, those of our members who have had high blood-glucose levels have not suffered from having those high BG levels to the same extent that a 'normal' individual would have done, as the VDR activation, and the Angiotensin receptor blockade, both produced by the Olmesartan, have protected their bodies from the expected damage." Trevor Marshall </blockquote>
Line 94: Line 98:
    
  
-Helicobacter pylori eradication led to a reduction in insulin resistance(({{pubmed>long:20134372}})). +Helicobacter pylori eradication led to a reduction in insulin resistance(({{pmid>long:20134372}})). 
-The use of oxytetracycline in obese mice reduced insulin resistance(({{pubmed>long:4464837}}))+The use of oxytetracycline in obese mice reduced insulin resistance(({{pmid>long:4464837}}))
  
  
  
-Diabetes can cause a sugar coating that smothers body's immune defences (({{pubmed>long:20674073}}))+Diabetes can cause a sugar coating that smothers body's immune defences (({{pmid>long:20674073}}))
  
 The researchers looked at the similarities in chemical structure between glucose in blood and body fluids, and two other sugar called mannose and fucose. These sugars are found on the surfaces of bacteria and fungi and act as targets for receptors in our body that have evolved to detect and bind to microbial sugars to then combat the infection.  The researchers looked at the similarities in chemical structure between glucose in blood and body fluids, and two other sugar called mannose and fucose. These sugars are found on the surfaces of bacteria and fungi and act as targets for receptors in our body that have evolved to detect and bind to microbial sugars to then combat the infection. 
Line 109: Line 113:
  
  
-[[http://tinyurl.com/yrjqa3|Burden of Infection and Insulin Resistance in Healthy Middle-Aged Men]]+[[https://tinyurl.com/yrjqa3|Burden of Infection and Insulin Resistance in Healthy Middle-Aged Men]]
  
  
Line 129: Line 133:
 diabetes, sarcoidosis, irritable bowel syndrome diabetes, sarcoidosis, irritable bowel syndrome
  
-Read the [[http://bacteriality.com/2008/06/19/interview22/|interview]]+Read the [[https://bacteriality.com/2008/06/19/interview22/|interview]]
  
 <html></div></div> <html></div></div>
Line 164: Line 168:
  
  
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
Line 314: Line 319:
  s177, s178:  s177, s178:
 Read first: Read first:
-(({{pubmed>long:20140211}}))+(({{pmid>long:20140211}}))
  
  
  
    
-http://www.ncbi.nlm.nih.gov/pubmed/19225551+https://www.ncbi.nlm.nih.gov/pubmed/19225551
  
  
-egg consumption and diabetes(({{pubmed>long:18400720}}))+egg consumption and diabetes(({{pmid>long:18400720}}))
  
  
Line 339: Line 344:
  
  
-10 Kramer, Hilary. “Diabetes is Killing our Economy”. Forbes.com. 13 Jan 2010. <http://www.forbes.com/2010/01/13/kramer-obesity-nutrition-intelligent-investing-diabetes.html>;+10 Kramer, Hilary. “Diabetes is Killing our Economy”. Forbes.com. 13 Jan 2010. <https://www.forbes.com/2010/01/13/kramer-obesity-nutrition-intelligent-investing-diabetes.html>;
  
  
Line 386: Line 391:
 It is well documented, over several decades, that the BCG vaccine causes Sarcoidosis, eg It is well documented, over several decades, that the BCG vaccine causes Sarcoidosis, eg
 "Juvenile sarcoidosis after BCG vaccination (2006)" "Juvenile sarcoidosis after BCG vaccination (2006)"
-http://www.ncbi.nlm.nih.gov/pubmed/12734491+https://www.ncbi.nlm.nih.gov/pubmed/12734491
  
 "Juvenile sarcoidosis after BCG vaccination (1989)" "Juvenile sarcoidosis after BCG vaccination (1989)"
-http://www.ncbi.nlm.nih.gov/pubmed/2602688+https://www.ncbi.nlm.nih.gov/pubmed/2602688
  
 "Incidence of Intrathoracic Sarcoidosis among young adults participating in a trial of Tuberculosis vaccines (1965)" "Incidence of Intrathoracic Sarcoidosis among young adults participating in a trial of Tuberculosis vaccines (1965)"
-http://www.ncbi.nlm.nih.gov/pubmed/14321221+https://www.ncbi.nlm.nih.gov/pubmed/14321221
  
 The use of BCG vaccine has been banned in several countries , as being unsafe. Its use in Diabetes is not even a new idea, having been first mooted in 1991 The use of BCG vaccine has been banned in several countries , as being unsafe. Its use in Diabetes is not even a new idea, having been first mooted in 1991
-http://www.ncbi.nlm.nih.gov/pubmed/1833072+https://www.ncbi.nlm.nih.gov/pubmed/1833072
  
 Anybody who is researching the use of live vaccines, and who doesn't know about the terrible track record of BCG, needs to have their researchers' licenses stripped from them, in my opinion. ..Trevor.. Anybody who is researching the use of live vaccines, and who doesn't know about the terrible track record of BCG, needs to have their researchers' licenses stripped from them, in my opinion. ..Trevor..
Line 493: Line 498:
  
 The renin-angiotensin-aldosterone system and the eye in diabetes. The renin-angiotensin-aldosterone system and the eye in diabetes.
-http://tinyurl.com/67ldp+https://tinyurl.com/67ldp
  
 Immuno-localization of the calcitriol receptor, calbindin-D28k and the plasma membrane calcium pump in the human eye. Immuno-localization of the calcitriol receptor, calbindin-D28k and the plasma membrane calcium pump in the human eye.
-http://tinyurl.com/552tv+https://tinyurl.com/552tv
  
 Retinopathy Retinopathy
Line 502: Line 507:
 Retinopathy, in general, is a very common occurrence in Type 1 Diabetics, many of whom end up blinded by it.  Retinopathy, in general, is a very common occurrence in Type 1 Diabetics, many of whom end up blinded by it. 
  
-A similar process, macular degeneration, is an inflammatory process (see http://tinyurl.com/yjthzk ).+A similar process, macular degeneration, is an inflammatory process (see https://tinyurl.com/yjthzk ).
  
-Reduction of retinopathy during the course of the MP (in others) would tend to indicate it is also an inflammatory process. However, several of my Diabetes-research colleagues were convinced it was caused by the body failing to assimilate exogenous insulin correctly. see diagram summarizing some of the key relationships between the body's hormones and 1,25-D. You can access it at http://autoimmunityresearch.org/hormones.pdf+Reduction of retinopathy during the course of the MP (in others) would tend to indicate it is also an inflammatory process. However, several of my Diabetes-research colleagues were convinced it was caused by the body failing to assimilate exogenous insulin correctly. see diagram summarizing some of the key relationships between the body's hormones and 1,25-D. You can access it at https://autoimmunityresearch.org/hormones.pdf
  
 Be careful of the lasers. Th1 tissues don't heal as easily, and certainly not when a lot of incident radiation has been focused on them (excess Vit D production).  Be careful of the lasers. Th1 tissues don't heal as easily, and certainly not when a lot of incident radiation has been focused on them (excess Vit D production). 
Line 552: Line 557:
 Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes
  
-http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61032-X/abstract+https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61032-X/abstract
  
                                    2nd lot of notes & COMMENTS                                    2nd lot of notes & COMMENTS
Line 566: Line 571:
   * Legacy content   * Legacy content
  
-http://www.lipidsonline.org/news/article.cfm?aid=9682+https://www.lipidsonline.org/news/article.cfm?aid=9682
  
  
  
  
-<blockquote>Conversely, harmful bacteria may deregulate genes mediating energy metabolism, and can produce toxins that mutate DNA, affecting the nervous and immune systems. The outcome is various forms of chronic disease, including obesity, diabetes and even cancers.(({{pubmed>long:17210919}})) (({{pubmed>long:17456850}})) (({{pubmed>long:17456850}}))+<blockquote>Conversely, harmful bacteria may deregulate genes mediating energy metabolism, and can produce toxins that mutate DNA, affecting the nervous and immune systems. The outcome is various forms of chronic disease, including obesity, diabetes and even cancers.(({{pmid>long:17210919}})) (({{pmid>long:17456850}})) (({{pmid>long:17456850}}))
  
 //**Liping Zhao**//</blockquote> //**Liping Zhao**//</blockquote>
Line 577: Line 582:
  
 <blockquote>Diabetes. 2007 Jul;56(7):1761-72. Epub 2007 Apr 24. <blockquote>Diabetes. 2007 Jul;56(7):1761-72. Epub 2007 Apr 24.
-Metabolic endotoxemia initiates obesity and insulin resistance.(({{pubmed>long:17456850}}))+Metabolic endotoxemia initiates obesity and insulin resistance.(({{pmid>long:17456850}}))
  
 Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R.
Line 591: Line 596:
 From: Sue Lyons From: Sue Lyons
 Date: 2011-03-24 20:44:55 Date: 2011-03-24 20:44:55
-Reply: http://www.marshallprotocol.com/reply.php?topic_id=7078+Reply: https://www.marshallprotocol.com/reply.php?topic_id=7078
  
 Janet, your suggestions to watch my blood sugar closely was timely as the day you wrote to me, I had a very low blood sugar episode while exercising!  I immediately stopped all diabetes meds and exercising until my blood sugar became more stable!  Thank you for the advise!   Janet, your suggestions to watch my blood sugar closely was timely as the day you wrote to me, I had a very low blood sugar episode while exercising!  I immediately stopped all diabetes meds and exercising until my blood sugar became more stable!  Thank you for the advise!  
Line 640: Line 645:
 </blockquote> </blockquote>
 <blockquote>Effects of Olmesartan Medoxomil, an Angiotensin II Type 1 Receptor Antagonist, on Plasma Concentration of B-Type Natriuretic Peptide, in Hypertensive Patients with Type 2 Diabetes Mellitus: A Preliminary, Observational, Open-Label Study. <blockquote>Effects of Olmesartan Medoxomil, an Angiotensin II Type 1 Receptor Antagonist, on Plasma Concentration of B-Type Natriuretic Peptide, in Hypertensive Patients with Type 2 Diabetes Mellitus: A Preliminary, Observational, Open-Label Study.
-http://www.ncbi.nlm.nih.gov/pubmed/21184621+https://www.ncbi.nlm.nih.gov/pubmed/21184621
  
 Angiotensin II type 1 (AT(1)) receptor antagonists (angiotensin receptor blockers [ARBs]) are widely used for the treatment of not only hypertension but also cardiac dysfunction. B-type natriuretic peptide (BNP) is secreted mainly by the cardiac ventricle and plays an important role in the regulation of blood pressure (BP) and body fluid. It has been established that the plasma level of BNP is increased in patients with chronic heart failure in proportion to the severity of cardiac dysfunction. Because cardiac dysfunction is closely associated with a high risk of mortality in patients with diabetes mellitus, early identification and prevention of cardiac dysfunction are important. The objective of this study was to determine the effects of olmesartan medoxomil, a novel ARB, on the plasma level of BNP in hypertensive patients with type 2 diabetes. Methods: This was a preliminary, prospective, observational, open-label study. Sixty-eight type 2 diabetic patients with hypertension (systolic BP [SBP] 140 mmHg or diastolic BP [DBP] 90 mmHg) received olmesartan medoxomil 10-20 mg/day for 24 weeks. Plasma levels of BNP, as well as several clinical parameters of glycaemic control and lipid metabolism, were compared before and after 24 weeks of treatment. Another group consisting of 22 age- and body mass index-matched subjects not treated with olmesartan medoxomil was observed for reference purposes. Results: In the olmesartan medoxomil group, mean ± SD SBP decreased from 152.8 ± 16.4 at baseline to 146.8 ± 14.4 mmHg after 24 weeks' treatment (p < 0.05); similarly, mean ± SD DBP decreased from 85.6 ± 10.5 to 81.3 ± 11.6 mmHg (p < 0.05). In 53 subjects in whom plasma levels of BNP could be measured both before and after treatment, mean ± SD BNP decreased from 41.3 ± 49.9 to 32.5 ± 36.3 pg/mL (p < 0.05). Change in plasma BNP level over the 24-week treatment period in the olmesartan medoxomil group was not correlated with change in SBP or DBP. Multiple regression analysis revealed that change in plasma BNP level was not correlated with baseline value of or change in any other parameters. No other parameters in the olmesartan medoxomil group, and no parameters in the non-olmesartan medoxomil reference group, showed significant changes. Conclusion: The current preliminary study showed that olmesartan medoxomil treatment might decrease plasma BNP levels, independent of its BP-lowering effect, in hypertensive patients with type 2 diabetes. Angiotensin II type 1 (AT(1)) receptor antagonists (angiotensin receptor blockers [ARBs]) are widely used for the treatment of not only hypertension but also cardiac dysfunction. B-type natriuretic peptide (BNP) is secreted mainly by the cardiac ventricle and plays an important role in the regulation of blood pressure (BP) and body fluid. It has been established that the plasma level of BNP is increased in patients with chronic heart failure in proportion to the severity of cardiac dysfunction. Because cardiac dysfunction is closely associated with a high risk of mortality in patients with diabetes mellitus, early identification and prevention of cardiac dysfunction are important. The objective of this study was to determine the effects of olmesartan medoxomil, a novel ARB, on the plasma level of BNP in hypertensive patients with type 2 diabetes. Methods: This was a preliminary, prospective, observational, open-label study. Sixty-eight type 2 diabetic patients with hypertension (systolic BP [SBP] 140 mmHg or diastolic BP [DBP] 90 mmHg) received olmesartan medoxomil 10-20 mg/day for 24 weeks. Plasma levels of BNP, as well as several clinical parameters of glycaemic control and lipid metabolism, were compared before and after 24 weeks of treatment. Another group consisting of 22 age- and body mass index-matched subjects not treated with olmesartan medoxomil was observed for reference purposes. Results: In the olmesartan medoxomil group, mean ± SD SBP decreased from 152.8 ± 16.4 at baseline to 146.8 ± 14.4 mmHg after 24 weeks' treatment (p < 0.05); similarly, mean ± SD DBP decreased from 85.6 ± 10.5 to 81.3 ± 11.6 mmHg (p < 0.05). In 53 subjects in whom plasma levels of BNP could be measured both before and after treatment, mean ± SD BNP decreased from 41.3 ± 49.9 to 32.5 ± 36.3 pg/mL (p < 0.05). Change in plasma BNP level over the 24-week treatment period in the olmesartan medoxomil group was not correlated with change in SBP or DBP. Multiple regression analysis revealed that change in plasma BNP level was not correlated with baseline value of or change in any other parameters. No other parameters in the olmesartan medoxomil group, and no parameters in the non-olmesartan medoxomil reference group, showed significant changes. Conclusion: The current preliminary study showed that olmesartan medoxomil treatment might decrease plasma BNP levels, independent of its BP-lowering effect, in hypertensive patients with type 2 diabetes.
Line 697: Line 702:
 1. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. 1. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
  
-//**H.H. Weng**//(({{pubmed>long:18827215}}))+//**H.H. Weng**//(({{pmid>long:18827215}}))
 </blockquote> </blockquote>
  
Line 723: Line 728:
  
 find more about Barney's blood glucose - very high find more about Barney's blood glucose - very high
-- http://www.bbc.co.uk/blogs/today/tomfeilden/2008/10/drugs_on_test.html+- https://www.bbc.co.uk/blogs/today/tomfeilden/2008/10/drugs_on_test.html
  
  
Line 745: Line 750:
  
  
-Glucose test is [[http://labtestsonline.org/understanding/analytes/glucose/test.html|described here]].+Glucose test is [[https://labtestsonline.org/understanding/analytes/glucose/test.html|described here]].
  
 Blood glucose meters Blood glucose meters
Line 795: Line 800:
  
 </blockquote> </blockquote>
-===== References =====+===== References =====</nodisp> 
home/diseases/diabetes2.1550612415.txt.gz · Last modified: 02.19.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.